SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma
Science Translational Medicine · 15.05.2024 · 16 (747)
DOI: 10.1126/scitranslmed.adj7685 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 15.05.2024. Verfasst von Iris S Luk und 21 weiteren Autor:innen. Beteiligte Einrichtung: Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Hauptthemen laut MEDLINE: Adaptor Proteins, Signal Transducing, Cholangiocarcinoma, Dasatinib, Isocitrate Dehydrogenase. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Intrahepatic cholangiocarcinoma (ICC) is an aggressive bile duct malignancy that frequently exhibits isocitrate dehydrogenase ( IDH1/IDH2 ) mutations. Mutant IDH (IDHm) ICC is dependent on SRC kinase for growth and survival and is hypersensitive to inhibition by dasatinib, but the molecular mechanism underlying this sensitivity is unclear. We found that dasatinib reduced p70 S6 kinase (S6K) and ribosomal protein S6 (S6), leading to substantial reductions in cell size and de novo protein synthesis. Using an unbiased phosphoproteomic screen, we identified membrane-associated guanylate kinase, WW, and PDZ domain containing 1 (MAGI1) as an SRC substrate in IDHm ICC. Biochemical and functional assays further showed that SRC inhibits a latent tumor-suppressing function of the MAGI1–protein phosphatase 2A (PP2A) complex to activate S6K/S6 signaling in IDHm ICC. Inhibiting SRC led to activation and increased access of PP2A to dephosphorylate S6K, resulting in cell death. Evidence from patient tissue and cell line models revealed that both intrinsic and extrinsic resistance to dasatinib is due to increased phospho-S6 (pS6). To block pS6, we paired dasatinib with the S6K/AKT inhibitor M2698, which led to a marked reduction in pS6 in IDHm ICC cell lines and patient-derived organoids in vitro and substantial growth inhibition in ICC patient-derived xenografts in vivo. Together, these results elucidated the mechanism of action of dasatinib in IDHm ICC, revealed a signaling complex regulating S6K phosphorylation independent of mTOR, suggested markers for dasatinib sensitivity, and described a combination therapy for IDHm ICC that may be actionable in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
- Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
- Gastrointestinal and Endocrine Tumor Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
- Department of Surgery, University of Washington, Seattle, WA 98195, USA.
- Medical Scientist Training Program, University of Washington, Seattle, WA 98195, USA.
ORCID-Profile: Iris S Luk, Caroline M Bridgwater, Liberalis D Boila, Mariana Yáñez-Bartolomé, Aaron E Lampano, Taylor S Hulahan, Myriam Boukhali, Naomi Yamamoto, David Sokolov, Ian A Engstrom, Lucas B Sullivan, Paul D Lampe, Jonathan A Cooper, Wilhelm Haas, Sita Kugel
Förderung
- NCI NIH HHS
Zitieren
APA
Luk, I. S., Bridgwater, C. M., Yu, A., Boila, L. D., Yáñez-Bartolomé, M., Lampano, A. E., Hulahan, T. S., Boukhali, M., Kathiresan, M., Macarulla, T., Kenerson, H. L., Yamamoto, N., Sokolov, D., Engstrom, I. A., Sullivan, L. B., Lampe, P. D., Cooper, J. A., Yeung, R. S., Tian, T. V., …, & Kugel, S. (2024). SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma. Science Translational Medicine, 16(747). https://doi.org/10.1126/scitranslmed.adj7685
Vancouver
Luk IS, Bridgwater CM, Yu A, Boila LD, Yáñez-Bartolomé M, Lampano AE, et al. SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma. Science Translational Medicine. 2024;16(747). doi:10.1126/scitranslmed.adj7685
BibTeX
@article{Luk2024,
author = {Luk, Iris S and Bridgwater, Caroline M and Yu, Angela and Boila, Liberalis D and Yáñez-Bartolomé, Mariana and Lampano, Aaron E and Hulahan, Taylor S and Boukhali, Myriam and Kathiresan, Meena and Macarulla, Teresa and Kenerson, Heidi L and Yamamoto, Naomi and Sokolov, David and Engstrom, Ian A and Sullivan, Lucas B and Lampe, Paul D and Cooper, Jonathan A and Yeung, Raymond S and Tian, Tian V and Haas, Wilhelm and Saha, Supriya K and Kugel, Sita},
title = {SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma},
journal = {Science Translational Medicine},
year = {2024},
volume = {16},
number = {747},
doi = {10.1126/scitranslmed.adj7685}
}
EUVIMED